EUROAPI moves forward with carbon reduction ambitions
EUROAPI has announced the initiation of a €24 million investment for the construction of a state-of-the-art biomass boiler at its Saint-Aubin-lès-Elbeuf (Seine-Maritime, France) site that is planned to be activated in 2025. This investment should enable EUROAPI to support the site’s vitamin B12 production capacity increase programme, reduce its CO2 emissions by almost 76 percent in 2026, compared to 2020 and support the Group’s strategy towards greater energy autonomy.
The design and engineering of the biomass boiler have already been finalised and the construction will start in the coming weeks. This 17 MW equipment will use waste wood (Grade B) and is expected to produce 140,000 tonnes of steam per year, enabling EUROAPI to cut its yearly fossil fuel CO2 emissions by approximately 20,000 tonnes. It could also allow the production of green electricity by using cogeneration technology, covering 10 percent of the needs onsite, and supply local community heating networks.
This investment is a key milestone for EUROAPI, in line with its ambitious ESG roadmap. It confirms its target to reduce its CO2 emissions (scopes 1 and 2) by 30 percent in 2030 compared to 2020. In the context of inflation and rising energy prices, this project well illustrates EUROAPI’s strategy towards greater energy autonomy.
The scheme benefits from the financial support of €10.4 million from the French Government within the framework of the France Relance plan operated by ADEME. Being awarded by this selection program is a true recognition of EUROAPI’s efforts in favour of decarbonisation.
“This major investment in Saint-Aubin-lès-Elbeuf will enable us to reduce our gas consumption and to produce 76 percent of the total site steam with no CO2 emission in 2025. It bolsters our commitment to delivering our ESG roadmap and more particularly to our industrial process decarbonisation initiative,” commented Karl Rotthier, chief executive officer of EUROAPI.
“I am particularly proud that the quality of this project has allowed the Group to be selected by the France Relance program and to benefit from strong financial support. This new generation of equipment will also allow us to reduce the amount of energy required for the fermentation process behind the production of vitamin B12” added Eric Berger, chief operating officer of EUROAPI.
The Saint-Aubin-lès-Elbeuf factory is one of the six EUROAPI sites. It is specialised in large scale fermentation and has downstream processing facilities. The plant has health authority, GMP and ISO certifications and operates based on the highest industrial standards. It is the only Western API manufacturing site of vitamin B12 for the pharmaceutical industry and plays a crucial role in ensuring its global supply.
The design and engineering of the biomass boiler have already been finalised and the construction will start in the coming weeks. This 17 MW equipment will use waste wood (Grade B) and is expected to produce 140,000 tonnes of steam per year, enabling EUROAPI to cut its yearly fossil fuel CO2 emissions by approximately 20,000 tonnes. It could also allow the production of green electricity by using cogeneration technology, covering 10 percent of the needs onsite, and supply local community heating networks.
This investment is a key milestone for EUROAPI, in line with its ambitious ESG roadmap. It confirms its target to reduce its CO2 emissions (scopes 1 and 2) by 30 percent in 2030 compared to 2020. In the context of inflation and rising energy prices, this project well illustrates EUROAPI’s strategy towards greater energy autonomy.
The scheme benefits from the financial support of €10.4 million from the French Government within the framework of the France Relance plan operated by ADEME. Being awarded by this selection program is a true recognition of EUROAPI’s efforts in favour of decarbonisation.
“This major investment in Saint-Aubin-lès-Elbeuf will enable us to reduce our gas consumption and to produce 76 percent of the total site steam with no CO2 emission in 2025. It bolsters our commitment to delivering our ESG roadmap and more particularly to our industrial process decarbonisation initiative,” commented Karl Rotthier, chief executive officer of EUROAPI.
“I am particularly proud that the quality of this project has allowed the Group to be selected by the France Relance program and to benefit from strong financial support. This new generation of equipment will also allow us to reduce the amount of energy required for the fermentation process behind the production of vitamin B12” added Eric Berger, chief operating officer of EUROAPI.
The Saint-Aubin-lès-Elbeuf factory is one of the six EUROAPI sites. It is specialised in large scale fermentation and has downstream processing facilities. The plant has health authority, GMP and ISO certifications and operates based on the highest industrial standards. It is the only Western API manufacturing site of vitamin B12 for the pharmaceutical industry and plays a crucial role in ensuring its global supply.
